Effect of angiotensin-converting enzyme inhibition on survival in 3773 Chinese type 2 diabetic patients

Hypertension

Volumn 44, Issue 3, 2004, Pages 294-299

  So, Wing Yee ^a   Ozaki, Risa ^a   Chan, Norman N ^a   Tong, Peter C Y ^a   Ho, Chung Shun ^a   Lam, Christopher W K ^a   Ko, Gary T C ^a   Chow, Chun Chung ^a   Chan, Wing Bun ^a   Ma, Ronald C W ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Angiotensin converting enzyme; Cardiovascular diseases; Diabetes mellitus; Renal disease

Indexed keywords

ALBUMIN; ANGIOTENSIN II ANTAGONIST; CANDESARTAN; CAPTOPRIL; CHOLESTEROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; GLUCOSE; HEMOGLOBIN A1C; LISINOPRIL; LOSARTAN; PERINDOPRIL; RAMIPRIL; VALSARTAN;

ADULT; ARTICLE; BLOOD PRESSURE; CAUSE OF DEATH; CHINESE; COHORT ANALYSIS; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; ENZYME INHIBITION; FEMALE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; TREATMENT OUTCOME;

ADULT; AGED; ALBUMINURIA; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; COHORT STUDIES; DIABETES COMPLICATIONS; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DIABETIC NEPHROPATHIES; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HONG KONG; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 4444329419     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000137192.19577.c3     Document Type: Article

References (19)

1. End-stage renal disease attributed to diabetes among American Indians/Alaska Natives with diabetes-United States, 1990-1996. MMWR Morb Mortal Wkly Rep. 2000;49:959-962.
2. Colhoun HM, Lee ET, Bennett PH, Lu M, Keen H, Wang SL, Stevens LK, Fuller JH. Risk factors for renal failure: the WHO Mulinational Study of Vascular Disease in Diabetes. Diabetologia. 2001;44:(Suppl 2):S46-S53.
3. Chan JC, Ko GT, Leung DH, Cheung RC, Cheung MY, So WY, Swaminathan R, Nicholls MG, Critchley JA, Cockram CS. Long-term effects of angiotensin- converting enzyme inhibition and metabolic control in hypertensive type 2 diabetic patients. Kidney Int. 2000;57:590-600.
4. Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med. 2000;160:1093-1100.
5. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Halle JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA. 2001;286:421-426.
6. Hear Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253-259.
7. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851-860.
8. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861-869.
9. Okin PM, Devereux RB, Jern S, Kjeldsen SE, Julius S, Nieminen MS, Snapinn S, Harris KE, Aurup P, Edelman JM, Dahlof B. Regression of electrocardiographic left ventricular hypertrophy by losartan versus atenolol: the Losartan Intervention for Endpoint reduction in Hypertension (LIFE) study. Circulation. 2003;108:684-690.
10. Schrier RW, Estacio RO, Esler A, Mehler P. Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int. 2002;61:1086-1097.
11. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R. Use of enalapril to attenuate decline in renal function in normotensive, normoal-buminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med. 1998;128:982-988.
12. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998;317:713-720.
13. Piwernetz K, Home PD, Snorgaard O, Antsiferov M, Staehr-Johansen K, Krans M. For the DiabCare Monitoring Group of the St. Vincent Declaration Steering Committee. Monitoring the targets of the St. Vincent declaration and the implementation of quality management in diabetes care: the DiabCare initiative. Diabetic Medicine. 1993;10:371-377.
14. Laakso M, Pyorala K. Age of onset and type of diabetes. Diabetes Care. 1985;8:114-117.
15. Mogensen CE, Vestbo E, Poulsen PL, Christiansen C, Damsgaard EM, EiskjÆr H, FrØland A, Hansen KW, Nielsen S, Pedersen MM. Microalbuminuria and potential confounders. Diabetes Care. 1995;18:572-581.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
17. Viberti G, Chaturvedi N. Angiotensin converting enzyme inhibitors in diabetic patients with microalbuminuria or normoalbuminuria. Kidney Int Suppl. 1997;63:S32-S35.
18. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL, Meredith PA, Murray LS, Reid JL, Robertson JW. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet. 1998;352:179-184.
19. Felmeden DC, Lip GY. Antihypertensive therapy and cancer risk. Drug Saf. 2001;24:727-739.